Cash Flow Trend (5 Years)
Investing CF
Operating CF
Financing CF
23.8M0
-19.5M
00002021
2022
2023
2024
100,926
23.8M
-19.5M
NGENNervGen Pharma Corp. Common stock$ --
NervGen Pharma Corp. Common stock
NGEN
$ -
-
Review operating, investing, and financing cash flow trends alongside detailed breakdowns.
account_balanceCash Flow (CF) Summary
No cash flow data available
2025
analyticsInvestment Efficiency Analysis
Operating CF vs Investing CF
Operating CF
Investing CF
40M20M0-20M-40M
20212022202320242025
waterfall_chartCash Flow Bridge (FY2025 Full Year)
Beginning / Ending
Increase
Decrease
30M20M10M0-10M
17.3M
Beginning Cash
-19.5M
Operating CF
100,926
Investing CF
23.8M
Financing CF
436,494
Other
22.1M
Ending Cash
Cash Flow Details
Item
Net Income from Continuing Operations
Depreciation and Amortization
Depreciation and Amortization
Stock-based Compensation
Other Non-cash Items
Adjustments to Net Income
Other Operating Activity
Change in Working Capital
Change in Account Receivables
Change in Trade Receivables
Change in Inventory
Change in Payables and Accrued Expenses
Other Working Capital Changes
Cash Flow from Operating Activities
Net Fixed Asset Activity
Net Investment Securities Activity
Other Investing Activity
Cash Flow from Investing Activities
Net Borrowings
Net Issuance / Repurchase of Stock
Issuance of Capital Stock
Total Dividends Paid
Net Dividends Paid
Treasury / Other Financing Activity
Cash Flow from Financing Activities
Beginning Cash and Cash Equivalents
Net Change in Cash and Cash Equivalents
Net Change in Cash and Cash Equivalents
Exchange Rate Changes
Ending Cash and Cash Equivalents
Free Cash Flow
Unlock Long-Term Cash Flow Data
Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.